Mesoblast successfully completes placement and accelerated entitlement offer

New york, march 13, 2024 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm commitments to complete its pro-rata accelerated non-renounceable entitlement offer that was launched on 4 december, 2023 (entitlement offer). together the entitlement offer and institutional placement raised gross proceeds of a$97 million, including a$36.7 million committed today on the same terms as the entitlement offer, primarily from mesoblast's existing major shareholders.
MESO Ratings Summary
MESO Quant Ranking